SCHEMBL470317

SCHEMBL470317

Clc1cc2c(Br)cccc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.45
NOS1 P29475 1/20 0.42
AXL P30530 1/20 0.42
FLT3 P36888 1/20 0.42
ITK Q08881 1/20 0.42
HRH4 Q9H3N8 1/20 0.41
DAO P14920 1/20 0.37
PSMB8 P28062 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GPR3 P46089 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL598649 0.75 GAA (0.50) AHRNOS1AXLFLT3ITK
SCHEMBL28115418 0.75 FLT3 (0.49) AHRNOS1AXLFLT3ITK
SCHEMBL31098173 0.75 GAA (0.50) AHRNOS1AXLFLT3ITK
SCHEMBL31573292 0.75 DAO (0.49) HRH4DAOALDH1A1KDM4E
SCHEMBL27739684 0.75 DAO (0.53) AHRFLT3HRH4DAOALDH1A1
SCHEMBL28238792 0.75 AOC3 (0.47) AHRNOS1AXLFLT3ITK
SCHEMBL28245245 0.75 NR4A2 (0.43) AHRHRH4DAOPSMB8ALDH1A1
SCHEMBL31070422 0.75 AHR (0.45) AHRNOS1AXLFLT3ITK
SCHEMBL21356683 0.75 AHR (0.45) AHRNOS1AXLFLT3ITK
SCHEMBL31158392 0.75 PARP1 (0.50) ALDH1A1GPR3HSD17B10PARP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067667-A1 ORGANIC COMPOUND, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2024-02-29 US disclosed
US-20240067667-A1 ORGANIC COMPOUND, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) 2024-02-29 US disclosed
WO-2023092781-A1 PREPARATION METHOD FOR REVERSE OSMOSIS MEMBRANE, AND REVERSE OSMOSIS MEMBRANE PREPARED THEREBY 沃顿科技股份有限公司 2023-06-01 WO disclosed
CN-116159449-A Method for preparing reverse osmosis membrane and reverse osmosis membrane prepared by same 沃顿科技股份有限公司 2023-05-26 CN disclosed
US-9326987-B2 Indazole derivatives for use in the treatment of influenza virus infection GLAXO GROUP LIMITED (GB) 2016-05-03 US disclosed
US-9326987-B2 Indazole derivatives for use in the treatment of influenza virus infection GLAXO GROUP LIMITED (GB) 2016-05-03 US disclosed
US-9326987-B2 Indazole derivatives for use in the treatment of influenza virus infection GLAXO GROUP LIMITED (GB) 2016-05-03 US disclosed
US-20130165433-A1 Novel Use GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-06-27 US disclosed
US-20130165433-A1 Novel Use GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-06-27 US disclosed
US-20130165433-A1 Novel Use GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-06-27 US disclosed
US-20120238559-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-09-20 US disclosed
US-20120238559-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-09-20 US disclosed
US-20120238559-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-09-20 US disclosed
WO-2012032065-A1 INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION GLAXO GROUP LIMITED (GB) 2012-03-15 WO disclosed
WO-2011067364-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067667-A1 ORGANIC COMPOUND, MIXTURE, COMPOSITION, AND ORGANIC ELECTRONIC DEVICE ORC3, OR10J3, ESR1 AHR 1358/4885NOS1 1206/4885AXL 350/4885
US-20130165433-A1 Novel Use HAVCR2, MAVS, ENTPD5 AHR 569/4885NOS1 2765/4885AXL 1974/4885
US-20120238559-A1 NOVEL COMPOUNDS PIK3CA, PIK3CD, PIK3C2B AHR 4035/4885NOS1 3153/4885AXL 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.